<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="129534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02037776</url>
  </required_header>
  <id_info>
    <org_study_id>Tj43-p2-t1</org_study_id>
    <nct_id>NCT02037776</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety Study of Rikkunshito in Patients With Functional Dyspepsia</brief_title>
  <official_title>Double-blind Trial With Rikkunshito Versus Placebo on Efficacy and Safety in Patients With Functional Dyspepsia: Multi-center Study (DREAM Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka City University</source>
  <oversight_info>
    <authority>Japan: Ministry of Health, Labor and Welfare</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy and safety of Rikkunshito compared to
      placebo in Japanese subjects with Functional Dyspepsia.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">March 2016</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Global assessment of overall treatment efficacy (OTE)</measure>
    <time_frame>At 4 week after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Global assessment of overall treatment efficacy (OTE)</measure>
    <time_frame>At 8 week after treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Global overall symptom (GOS)</measure>
    <time_frame>At 0, 4,8 week after treatment (including 14 days prior)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">460</enrollment>
  <condition>Functional Dyspepsia</condition>
  <arm_group>
    <arm_group_label>Rikkunshito Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Rikkunshito</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rikkunshito</intervention_name>
    <description>- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks</description>
    <arm_group_label>Rikkunshito</arm_group_label>
    <other_name>Tsumura Rikkunshito</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rikkunshito placebo</intervention_name>
    <description>- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks</description>
    <arm_group_label>Rikkunshito Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  -Patients diagnosed with FD according to the ROME III criteria i) Criteria fulfilled
             for the last 3 months with symptom onset at least 6 months prior to obtaining
             informed consent ii) Have not received upper endoscopy within the last 6 months prior
             to enrollment and do not have evidence of structural/organic disease iii) Must have
             one or more of the following symptoms:

               1. Bothersome postprandial fullness

               2. Early satiation

               3. Epigastric pain

               4. Epigastric burning

          -  At least one of the FD-related symptoms on the Global Overall Symptom (GOS) scale
             (bothersome postprandial fullness, early satiation, epigastric pain, epigastric
             burning) is ≥4, whereas heartburn is ≤3.

          -  Total score of depression-related symptoms on Hospital Anxiety and Depression Score
             (HAD) is ≤10.

          -  Type of visit: Outpatient

          -  Provides voluntary informed consent after receiving adequate explanation and
             demonstrates thorough understanding of the nature of the study.

        Exclusion Criteria:

          -  Confirmed ulcer (excluding scars) or malignant tumor in the upper GI

          -  Suspected organic lesions in the hepato-biliary-pancreatic regions such as
             cholelithiasis, hepatitis, pancreatitis

          -  History of upper GI resection

          -  Serious complications (liver, kidney, heart, or blood disease or metabolic disease)

          -  Less than a year since testing positive for H. pylori or have undergone a successful
             eradication therapy

          -  Use of prohibited medications

          -  Neuropsychiatric disorders

          -  Use of or planned use of any investigational drugs

          -  Unable to take drugs orally

          -  History of allergic reactions to Kampo medicines

          -  Pregnant or lactating women or those who are planning to conceive during the study
             period

          -  Deemed ineligible by principal investigator or sub-investigator
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tetsuo Arakawa</last_name>
    <role>Study Director</role>
    <affiliation>Osaka City University Graduate School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kazunari Tominaga, M.D., Ph. D.</last_name>
    <phone>+81-6-6645-3811</phone>
    <email>tomy@med.osaka-cu.ac.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Osaka City University Graduate School of Medicine</name>
      <address>
        <city>Abeno-ku</city>
        <state>Osaka</state>
        <zip>545-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kazunari Tominaga, M.D., Ph. D.</last_name>
      <phone>+81-6-6645-3811</phone>
      <email>tomy@med.osaka-cu.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Tetsuo Arakawa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 14, 2014</lastchanged_date>
  <firstreceived_date>January 9, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Osaka City University</investigator_affiliation>
    <investigator_full_name>Kazunari Tominaga</investigator_full_name>
    <investigator_title>M.D., Ph.D.</investigator_title>
  </responsible_party>
  <keyword>Rikkunshito</keyword>
  <keyword>Double blind</keyword>
  <keyword>Functional dyspepsia (FD)</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dyspepsia</mesh_term>
    <mesh_term>Gastritis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
